Gemcitabine and treatment of diffuse large B-cell lymphoma in relapsed or refractory elderly patients: A prospective randomized trial in Algeria

Journal of Cancer Research and Therapeutics

Volumn 6, Issue 1, 2010, Pages 41-46

  Aribi, Mourad ^a   Mesli, Naima ^a   Remla, Nesrine ^a   Sari, Badr Eddine ^a   Taleb, Abdesselam ^a   Touhami, Hadj ^b   Bekadja, Mohamed Amine ^c   Zouaoui Benhadji, Zahia ^d   Bouzid, Kamel ^e   Meguenni, Kaoual ^a  

^a UNIVERSITY OF TLEMCEN   (Algeria)

^b Oran Medical Centre University   (Algeria)

^c EHU   (Algeria)

^d UNIVERSITY OF SIDI BEL ABBES   (Algeria)

^e Centre Pierre et Marie Curie   (Algeria)

Author keywords

Diffuse large B cell lymphoma; Elderly patients; Gemcitabine based therapy; Refractory; Relapse

Indexed keywords

CISPLATIN; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; GEMCITABINE; METHYLPREDNISOLONE SODIUM SUCCINATE;

ADULT; AGED; ALGERIA; ANEMIA; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INFECTION; LARGE CELL LYMPHOMA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SINGLE BLIND PROCEDURE; THROMBOCYTOPENIA; VOMITING;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CYTARABINE; DEOXYCYTIDINE; DEXAMETHASONE; DISEASE-FREE SURVIVAL; ETOPOSIDE; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; METHYLPREDNISOLONE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL;

EID: 77952633578     PISSN: 09731482     EISSN: 19984138     Source Type: Journal    
DOI: 10.4103/0973-1482.63572     Document Type: Article

References (45)

1. Rogers BB. Overview of non-Hodgkin's Lymphoma. Semin Oncol Nurs 2006;2:67-72.
2. Wood NH, Feller L, Raubenheimer EJ, Jadwat Y, Meyerov R, Lemmer J. Human immunodeficiency virus (HIV)-associated extranodal T cell non-Hodgkin lymphoma of the oral cavity. SADJ2008;63:158-61.
3. Matasar MJ, Zelenetz AD. Overview of lymphoma diagnosis and management. Radiol Clin North Am 2008;46:175-98.
4. Hadzi-Pecova L, Petrusevska G, Stojanovic A. Non-Hodgkin's lymphomas: Immunologic prognostic studies. Prilozi 2007;28:39-55.
5. Roullet MR, Cornfield DB. Large natural killer cell lymphoma arising from an indolent natural killer cell large granular lymphocyte proliferation. Arch Pathol Lab Med 2006;130:1712-4.
6. van der Waal RI, Huijgens PC, van der Valk P, van der Waal I. Characteristics of 40 primary extranodal non-Hodgkin lymphomas of the oral cavity in perspective of the new WHO classification and the International Prognostic Index. Int J Oral Maxillofac Surg 2005;34:391-5.
7. Soubeyran P, Monnereau A. Lymphomes et autres tumeurs hématologiques. Cancer du sujet âgé. In: Morère JF, Rainfray M, editors. Paris: Springer; 2006. p. 179-206.
8. Turner JJ, Hughes AM, Kricker A, Milliken S, Grulich A, Kaldor J, et al. WHO non-Hodgkin's lymphoma classification by criterion-based report review followed by targeted pathology review: An effective strategy for epidemiology studies. Cancer Epidemiol Biomarkers Prev 2005;14:2213-9.
9. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: Clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998;16:2780-95.
10. de Jong D, Enblad G. Inflammatory cells and immune microenvironment in malignant lymphoma. J Intern Med 2008;264:528-36.
11. Oguchi M, Gomi K, Shikama N. Non-Hodgkin's lymphoma. Nippon Igaku Hoshasen Gakkai Zasshi 2002;62:206-14.
12. World Health Organization. Classification of Tumours. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. Pathology and Genetics of Tumours of the Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2001. p. 75-118.
13. Cuenca X, Xhaard A, Mounier N. Prognostic factors in Hodgkin and non-Hodgkin lymphomas. Bull Cancer 2009;96:461-73.
14. Djavanmardi L, Oprean N, Alantar A, Bousetta K, Princ G. Malignant non-Hodgkin's lymphoma (NHL) of the jaws: A review of 16 cases. J Craniomaxillofac Surg 2008;36:410-4.
15. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328:1002-6.
16. Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: A randomised controlled trial (RICOVER-60). Lancet Oncol 2008;9:105-16.
17. Ilić I, Mitrović Z, Aurer I, Basić-Kinda S, Radman I, Ajduković R, et al. Lack of prognostic significance of the germinal-center phenotype in diffuse large B-cell lymphoma patients treated with CHOP-like chemotherapy with and without rituximab. Int J Hematol 2009;90:74-80.
18. Thieblemont C, Coiffier B. Lymphoma in older patients. J Clin Oncol 2007;25:1916-23.
19. Solal-Celigny P, Lepage E, Brousse N, Reyes F, Haioun C, Leporrier M, et al. Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. N Engl J Med 1993;329:1608-14.
20. Michallet AS, Coiffier B. Recent developments in the treatment of aggressive non-Hodgkin lymphoma. Blood Rev 2009;23:11-23.
21. Shipp MA, Harrington DP, Anderson JR, Armitage JO, Bonadonna G, Brittinger G, et al. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987-94.
22. Long J, Versea L. Treatment approaches and nursing considerations for non-Hodgkin's lymphoma. Semin Oncol Nurs 2006;22:97-106.
23. Ribera JM. Adverse prognosis of bulky disease in good-risk DLBCL. Lancet Oncol 2008;9:406-7.
24. Boehme V, Schmitz N, Zeynalova S, Loeffler M, Pfreundschuh M. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: An analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood 2009;113:3896-902.
25. Paccalin M, Lacotte-Thierry L, Delwail V. Treatment of high grade, disseminated non-Hodgkin's lymphoma in elderly patients. Rev Med Interne 2002;23:632-7.
26. Zelenetz AD, Horwitz S. The Non-Hodgkin's Lymphomas. In: Chang AE, Ganz PA, Hayes DF, Kinsella TJ, Pass HI, Schiller JH, et al., editors. Oncology: An evidence-based approach. New York: Springer Science and Business Media, Inc.; 2006. p. 1247-75.
27. Oztürk MA, Barişta I, Altundaǧ MK, Türker A, Yalçin S, Celik I, et al. Modified ESHAP as salvage chemotherapy for recurrent or refractory non-Hodgkin's lymphoma: Results of a single-center study of 32 patients: Modified etoposide, methylprednisolone, cytarabine and cisplatin. Chemotherapy 2002;48:252-8.
28. Bartlett NL, Niedzwiecki D, Johnson JL, Friedberg JW, Johnson KB, van Besien K, et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol 2007;18:1071-9.
29. Venkatesh H, Di Bella N, Flynn TP, Vellek MJ, Boehm KA, Asmar L. Results of a phase II multicenter trial of single-agent gemcitabine in patients with relapsed or chemotherapy-refractory Hodgkin's lymphoma. Clin Lymphoma 2004;5:110-5.
30. Fan Y, Huang ZY, Luo LH, Yu HF. Efficacy of GDP regimen (gemcitabine, dexamethasone, and cisplatin) on relapsed or refractory aggressive non-Hodgkin's Lymphoma: A report of 24 cases. Ai Zheng 2008;27:1222-5.
31. Fosså A, Santoro A, Hiddemann W, Truemper L, Niederle N, Buksmaui S, et al. Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 1999;17:3786-92.
32. Webb WR, Higgins CB. Thoracic imaging: Pulmonary and cardiovascular radiology. Philadelphia: Lippincott Williams and Wilkins; 2005.
33. Ferlay, Bray F, Pisani P, Parkin DM. GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide. IARC Cancer Base No. 5., Lyon: IARC Press; 2001.
34. Chow EJ, Holly EA. Blood transfusions as a risk factor for non-Hodgkin's lymphoma in the San Francisco Bay Area: A populationbased study. Am J Epidemiol 2002;155:725-31.
35. Wang R, Zhang Y, Lan Q, Holford TR, Leaderer B, Zahm SH, et al. Occupational exposure to solvents and risk of non-Hodgkin lymphoma in Connecticut women. Am J Epidemiol 2009;169:176-85.
36. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
37. Boudjerra N. Epidemiologie des lymphomes malins non hodgkiniens. Algerian Society of Hematology and Blood Transfusion. Available from: http://www.hematologie-dz.com/index.php3?page=ens-06. [cited 2009 Aug. 10].
38. Zinzani PL, Tani M, Fanti S, Stefoni V, Musuraca G, Castellucci P, et al. A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. Ann Oncol 2008;19:769-73. (Pubitemid 351461050)
39. Dumontet C, Morschhauser F, Solal-Celigny P, Bouafia F, Bourgeois E, Thieblemont C, et al. Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma. Br J Haematol 2001;113:772-8.
40. Savage DG, Rule SA, Tighe M, Garrett TJ, Oster MW, Lee RT, et al. Gemcitabine for relapsed or resistant lymphoma. Ann Oncol 2000;11:595-7.
41. Santoro A, Bredenfeld H, Devizzi L, Tesch H, Bonfante V, Viviani S, et al. Gemcitabine in the treatment of refractory Hodgkin's disease: Results of a multicenter phase II study. J Clin Oncol 2000;18:2615-9.
42. Zinzani PL, Bendandi M, Stefoni V, Albertini P, Gherlinzoni F, Tani M, et al. Value of gemcitabine treatment in heavily pre-treated Hodgkin's disease patients. Haematologica 2000;85:926-9.
43. Larson BJ, Waples JM, Pusateri A, Mendenhall NP, Lynch JW Jr. A phase II study of gemcitabine in patients with relapsed or refractory lowgrade non-Hodgkin lymphoma. Am J Clin Oncol 2005;28:165-8.
44. Ganjoo KN, Robertson MJ, Fisher W, Jung SH, McClean J, Huh SY, et al. A phase II study of single agent gemcitabine in relapsed or refractory follicular or small lymphocytic non-Hodgkin lymphomas: A Hoosier Oncology Group Study. Am J Clin Oncol 2005;28:169-72.
45. Peters GJ, Ruiz van Haperen VW, Bergman AM, Veerman G, Smitskamp-Wilms E, van Moorsel CJ, et al. Preclinical combination therapy with gemcitabine and mechanisms of resistance. Semin Oncol 1996;23:16-24.